CorMedix Inc (CRMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CorMedix Inc (CRMD) has a cash flow conversion efficiency ratio of 0.082x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.86 Million) by net assets ($374.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CorMedix Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how CorMedix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CRMD liabilities breakdown for a breakdown of total debt and financial obligations.
CorMedix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CorMedix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
N/A |
|
Matas A/S
CO:MATAS
|
0.111x |
|
Royce Micro Cap Closed Fund
NYSE:RMT
|
-0.003x |
|
Newtechwood Corp
SHE:301588
|
N/A |
|
ChinaEtek Service & Technology Co. Ltd.
SHE:301208
|
0.011x |
|
Beijing Tongyizhong New Material Technology Corp
SHG:688722
|
0.021x |
|
TPI POLENE POWER
BK:TPIPP-R
|
0.008x |
|
International Tower Hill Mines Ltd
TO:ITH
|
-0.017x |
Annual Cash Flow Conversion Efficiency for CorMedix Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of CorMedix Inc from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see market value of CorMedix Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $84.66 Million | $-50.61 Million | -0.598x | -9.18% |
| 2023-12-31 | $70.14 Million | $-38.41 Million | -0.548x | -23.79% |
| 2022-12-31 | $55.06 Million | $-24.36 Million | -0.442x | -31.31% |
| 2021-12-31 | $62.80 Million | $-21.16 Million | -0.337x | +32.18% |
| 2020-12-31 | $44.22 Million | $-21.97 Million | -0.497x | +21.96% |
| 2019-12-31 | $23.65 Million | $-15.05 Million | -0.637x | +86.75% |
| 2018-12-31 | $4.93 Million | $-23.70 Million | -4.803x | -20.86% |
| 2017-12-31 | $7.19 Million | $-28.59 Million | -3.974x | -217.97% |
| 2016-12-31 | $17.81 Million | $-22.27 Million | -1.250x | -239.34% |
| 2015-12-31 | $34.01 Million | $-12.53 Million | -0.368x | +78.82% |
| 2014-12-31 | $3.63 Million | $-6.32 Million | -1.739x | -293.32% |
| 2013-12-31 | $-4.02 Million | $-3.62 Million | 0.900x | -81.21% |
| 2012-12-31 | $-475.38K | $-2.28 Million | 4.788x | +194.03% |
| 2011-12-31 | $1.24 Million | $-6.30 Million | -5.092x | -907.15% |
| 2010-12-31 | $7.26 Million | $-3.67 Million | -0.506x | -446.48% |
| 2009-12-31 | $-14.71 Million | $-2.15 Million | 0.146x | -57.32% |
| 2008-12-31 | $-12.03 Million | $-4.11 Million | 0.342x | -- |
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Pict… Read more